stoxline Quote Chart Rank Option Currency Glossary
Aptevo Therapeutics Inc. (APVO)
0.8451  -0.113 (-11.79%)    04-12 16:00
Open: 0.9265
High: 0.9265
Volume: 774,426
Pre. Close: 0.958
Low: 0.8335
Market Cap: 1(M)
Technical analysis
2024-04-12 4:47:37 PM
Short term     
Mid term     
Targets 6-month :  5.05 1-year :  7.58
Resists First :  4.32 Second :  6.48
Pivot price 3.44
Supports First :  0.83 Second :  0.69
MAs MA(5) :  2.23 MA(20) :  3.83
MA(100) :  6.54 MA(250) :  27.57
MACD MACD :  -1.1 Signal :  -0.8
%K %D K(14,3) :  2 D(3) :  4.1
RSI RSI(14): 21.4
52-week High :  91.95 Low :  0.83
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ APVO ] has closed below the lower bollinger band by 7.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ APVO ] is to continue within current trading range. It is unclear right now based on current values. 126.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.93 - 0.93 0.93 - 0.94
Low: 0.82 - 0.83 0.83 - 0.83
Close: 0.83 - 0.84 0.84 - 0.85
Company Description

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Headline News

Sun, 14 Apr 2024
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Increase in Short Interest - Defense World

Thu, 11 Apr 2024
Nasdaq Jumps 250 Points; Crude Oil Down 1% - Aptevo Therapeutics (NASDAQ:APVO), Eliem Therapeutics (NASDA - Benzinga

Thu, 11 Apr 2024
Why Aptevo Therapeutics Stock Is Cratering - Aptevo Therapeutics (NASDAQ:APVO) - Benzinga

Thu, 11 Apr 2024
Aptevo Therapeutics slumps after discounted equity raise (NASDAQ:APVO) - Seeking Alpha

Thu, 11 Apr 2024
Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today? - InvestorPlace

Thu, 11 Apr 2024
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 1 (M)
Shares Float 0 (M)
Held by Insiders 0.7 (%)
Held by Institutions 8.3 (%)
Shares Short 29 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -67.07
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 27.62
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -61.2 %
Return on Equity (ttm) -123.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -42.04
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -0.02
PEG Ratio 0
Price to Book value 0.03
Price to Sales 0
Price to Cash Flow -0.05
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android